Introduction
============

The mammalian gut-dwelling genus *Enterococcus*, particularly *Enterococcus faecium* and *Enterococcus faecalis*, have rapidly emerged as troublesome nosocomial pathogens. This has primarily occurred due to a combination of favourable antibiotic selective pressures with respect to intrinsic resistances,^[@DKQ219C1]^ as well as an inherent propensity for inter- and intraspecies gene transfer^[@DKQ219C2]^ (for an excellent review, see Willems and Bonten^[@DKQ219C3]^). Plasmids and transposons have been shown to play key roles in the acquisition and dissemination of drug resistance in the genus *Enterococcus*.^[@DKQ219C4]--[@DKQ219C12]^ The emergence and rapid spread of glycopeptide-resistant *E. faecium* (GREF) has been a particular challenge, as there are few remaining options for antimicrobial treatment.^[@DKQ219C1]^ The first clinical GREF was discovered in France in 1986 and harboured the VanA-type plasmid pIP816.^[@DKQ219C13]^ Subsequently, nosocomial GREF has been reported worldwide, with an increasing prevalence in the USA in particular,^[@DKQ219C14]^ but also in European countries in recent years (<http://www.rivm.nl/earss/>). In addition to the limited options for GREF treatment, there is also a concern for further horizontal transfer of glycopeptide resistance determinants into more pathogenic Gram-positive species, such as *Staphylococcus aureus* and *Clostridium difficile.*^[@DKQ219C15]^ This is underscored by nine cases of VanA-type vancomycin-resistant *S. aureus* isolated in the USA since 2002, and the evidence for an enterococcal origin as well as plasmid-mediated transfer is compelling.^[@DKQ219C16]^ More sequence information on VanA-type plasmids from different reservoirs is necessary to clarify their role and function in the maintenance and dissemination of glycopeptide resistance determinants in *Enterococcus* spp.

The use of the glycopeptide avoparcin as an animal growth promoter in European countries provided the opportunity for a build-up of a community reservoir of GREF.^[@DKQ219C17],[@DKQ219C18]^ Avoparcin resistance mediates cross-resistance to vancomycin, a clinically important antibiotic,^[@DKQ219C19]^ and avoparcin was thus prohibited for further use in animal husbandry. However, diverse GREF strains have persisted on farms several years after the ban.^[@DKQ219C20]--[@DKQ219C22]^ The persistent GREF populations carry *vanA* plasmids harbouring the non-conjugative transposon Tn*1546*.^[@DKQ219C21],[@DKQ219C23]^ Tn*1546* is also frequently located on plasmids in GREF strains isolated from hospitalized patients and healthy volunteers in the community.^[@DKQ219C24]--[@DKQ219C26]^ The presence of conserved Tn*1546* elements in genomically heterogeneous *E. faecium* isolates from various environments suggests the spread of resistance by horizontal gene transfer.^[@DKQ219C27]^ We have previously reported the presence of a common 372 bp DNA stretch immediately flanking Tn*1546* in a polyclonal *E. faecium* population.^[@DKQ219C21],[@DKQ219C22]^ It was hypothesized that the *vanA* gene cluster (Tn*1546*) disseminates as a larger genetic unit than the transposon, but smaller than a plasmid, due to the heterogeneous plasmid sizes and restriction patterns observed in the strain collection examined.

The aim of this study was to increase the knowledge on enterococcal plasmid population genetics and dynamics, with an emphasis on *E. faecium vanA* plasmids. We present: (i) the complete sequence of the Tn*1546*-containing pIP816,^[@DKQ219C13]^ first isolated in France 1986; (ii) a partial sequence of the Tn*1546*-containing *E. faecium* pVEF4, isolated from a Norwegian poultry farm previously exposed to avoparcin; and (iii) 28 Tn*1546*-containing genetic fragments amplified and sequenced from diverse *E. faecium* strains. Comparative analyses suggest that a genetic unit larger than the 10.85 kbp Tn*1546* has facilitated the horizontal spread of plasmid-encoded glycopeptide resistance between different *E. faecium* clonal lineages. Sequence data indicate horizontal dissemination as a composite transposon. Lastly, a novel enterococcal group II intron was identified within the composite transposon of several of the *vanA* plasmids and is functionally analysed here. Group II introns are ribozymes that catalyse their own excision and ligation of flanking exon sequences.^[@DKQ219C28]^

Materials and methods
=====================

Bacterial strains and plasmids
------------------------------

The bacterial strains and plasmids, and their relevant characteristics are given in Table [1](#DKQ219TB1){ref-type="table"}. All strains were grown at 37°C using brain heart infusion (BHI) agar or broth (Fluka BioChemika). The VanA-positive strains of *E. faecium* were grown in media supplemented with 10 mg/L vancomycin (Sigma). Table 1The *vanA*-containing *E. faecium* strains used in this study and their characteristicsStrainGeographical originSample sourceEpidemiology^a^MLST/CC^b^PFGEReference/source^c^399/F99/H8Norwayhumancs195/CC97[@DKQ219C21]399/F99/A9Norwayanimalcs241/CC910A[@DKQ219C21]399/S99/A7NorwayanimalcsND11[@DKQ219C21]BM4147Francehumanci95/CC22ND[@DKQ219C13]399/F98/A4NorwayanimalcsND5[@DKQ219C21]BM4147-1France------95/CC22---[@DKQ219C13]399/F98/A1NorwayanimalcsND9[@DKQ219C21]399/F99/A8Norwayanimalcs9/CC911[@DKQ219C21]64/F98/H2Norwayhumancs242/ND14[@DKQ219C21]356/98/HNorwayhumancsNDND[@DKQ219C22]31/F01/HNorwayhumancsNDND[@DKQ219C22]399/F99/A10Norwayanimalcs310/CC95A[@DKQ219C21]64/F99/A6Norwayanimalcs146/ND15[@DKQ219C21]64/F99/H6Norwayhumancs246/CC917[@DKQ219C21]58/F01/HNorwayhumancsNDND[@DKQ219C22]399/F98/H2Norwayhumancs8/CC92[@DKQ219C21]399/S99/H6Norwayhumancs2/CC16[@DKQ219C21]64/F98/H1Norwayhumancs48/CC913[@DKQ219C21]64/F98/A3Norwayanimalcs8/CC920[@DKQ219C21]K8-61NorwayhumanciNDNDK-res^c^64/F98/A2Norwayanimalcs195/CC919[@DKQ219C21]TUH32-76Portugalhumanci132/CC17ND[@DKQ219C57]32/F02/HNorwayhumancsNDND[@DKQ219C22]K9-72NorwayhumanciNDNDK-res^c^64/S99/A5NorwayanimalcsND21[@DKQ219C21]TUH2-8SwedenhumanciNDNDK-res^c^TUH32-64UKhumanho18/CC17ND[@DKQ219C57]TUH32-71Netherlandshumanho16/CC17ND[@DKQ219C57]TUH32-72USAhumanho17/CC17ND[@DKQ219C57]TUH32-74USAhumanho20/NDND[@DKQ219C57]TUH32-77Portugalhumanci125/NDND[@DKQ219C57]TUH32-78Netherlandshumanci21/CC9ND[@DKQ219C57]TUH32-79Netherlandshumanhs5/CC5ND[@DKQ219C57]TUH43-7NorwayhumancsNDND[@DKQ219C22][^1][^2][^3][^4]

DNA sequencing and analyses of pIP816 and pVEF4
-----------------------------------------------

Plasmid DNA was isolated by alkaline lysis, as previously described.^[@DKQ219C21],[@DKQ219C29]^ The fragmentation of plasmid pIP816 and subsequent cloning in *Escherichia coli* was done with the TOPO shotgun subcloning kit, as described by the manufacturer (Invitrogen). Plasmid DNA was purified prior to sequencing with the Perfectprep Plasmid 96 Vac system (Eppendorf). Custom primers (Sigma--Genosys) were used in PCRs for gap closure. The sequencing was done using ABI BigDye terminator chemistry (Perkin--Elmer Applied Biosystems Inc.) with ABI3130XL automated sequencers. Assembly of the sequence data was done using the Staden package^[@DKQ219C30]^ and Phrap (<http://www.phrap.org/>). The initial plasmid sequence of pIP816 was presented as a poster at the International Symposium on Plasmid Biology, 2006.^[@DKQ219C31]^ The draft contig sequences of pVEF4 were provided by Macrogen, Korea, using BigDye chemistry and with a sequence depth of \>14× coverage. Further extensive primer walk and gap closure experiments were done; however, we did not succeed in plasmid closure. Artemis was used to annotate the nucleotide sequence of pIP816 and pVEF4.^[@DKQ219C32]^ GLIMMER was used to predict coding sequences (CDSs)^[@DKQ219C33]^ that were checked manually by correlation scores of the open reading frames with ≥50 amino acids. Sequence similarity searches by FASTA and BLASTP refined the predictions.^[@DKQ219C34],[@DKQ219C35]^

Five complete *E. faecium vanA* plasmids were published in the nucleotide databases EMBL, GenBank and DDBJ as of May 2010 (Table [2](#DKQ219TB2){ref-type="table"}). These plasmids as well as the partial pVEF4 sequence were analysed according to genetic composition and synteny using the Artemis Comparison Tool.^[@DKQ219C32]^ Table 2The completely sequenced *vanA* plasmids of enterococci as of May 2010PlasmidHost strainSize (kbp)ReferenceAccession numberpIP816*E. faecium* BM414734.6This studyAM296544pVEF1*E. faecium* 399/F99/H839.6[@DKQ219C11]AM410096pVEF2*E. faecium* 399/F99/A939.6[@DKQ219C11]AM410096pVEF3*E. faecium* 399/S99/A763.1[@DKQ219C58]AM931300pHTβ^a^*E. faecium* FH63.7[@DKQ219C59]AB183714[^5]

PCR amplification and DNA sequencing of fragments of *vanA* plasmids
--------------------------------------------------------------------

The DNA regions flanking the *vanA* gene cluster were also determined for 28 different *vanA* plasmids isolated from genomically diverse *E. faecium* strains of human or animal origin (Table [1](#DKQ219TB1){ref-type="table"}). Isolated plasmid DNA was treated with PlasmidSafe DNase (Epicentre), and subsequently digested separately with PstI, EcoRI and BamHI according to the manufacturer\'s protocol (New England BioLabs), and separated by agarose gel electrophoresis. Undigested plasmid DNA was used in PCR assays, where r*Tth* DNA polymerase (GeneAmp XL PCR Kit, Applied Biosystems) and JumpStart *Taq* DNA Polymerase (JumpStart ReadyMix *Taq*, Sigma) were used according to the manufacturers\' protocols to amplify DNA fragments up- and downstream of Tn*1546* using the primers specified in Table [3](#DKQ219TB3){ref-type="table"}. Four PCR assays with the following primer combinations were used: PCF1 and PCF2 (7.1 kb amplicon); PCF1 and PCF3 (7.6 kb amplicon); PCF1 and PCF4 (6.0 kb amplicon); and PCF5 and PCF6 (1.2 kb amplicon). The PCR cycling parameters used in the amplifications of long fragments were initial denaturation at 94°C for 3 min followed by 25 cycles of 94°C for 1 min and 64°C for 11 min, and a final extension at 72°C for 10 min. For the JumpStart *Taq* PCRs, the cycling parameters were denaturation at 94°C for 2 min followed by 30 cycles of denaturation (94°C, 30 s), annealing (58°C, 30 s) and extension (72°C, 1 min 30 s), and a final extension at 72°C for 5 min. PCR products were analysed by agarose gel electrophoresis. Positive PCR products were confirmed by sequencing, as described above. Custom sequencing primers were used for primer walking when necessary (primers not given). Table 3PCR and RT--PCR primers used in the studyPrimerSequence (5′--3′)Binding site or referencePCF1AGGGATTCGTCAGGAAAATAGGpVEF1 nt 19439--19460PCF2AGCGTGTATGGTTTCAATTCCpVEF1 nt 20705--20685PCF3TCTCTTACGATTTTCTCATCCACApVEF1 nt 26932--26909PCF4TCGTGACAATCGGAACTAAAACTpIP816 nt 27553--27575PCF5AGTAACAAAGAAAGCCCAATTATCApVEF1 nt 8748--8724PCF6ACTTTTAGTTGGCTTGGACTGAACpVEF1 nt 2742--2765giiFTGGAATGATAGGGTAACGIntron (5′ end, forward)giiF5TGGTTGCGAGACTTAGGAAAACIntron (3′ end, forward)giiR3AYACGGCGTTCCATCAAIntron (3′ end, reverse)giiR7TAAGGTATAAGGTGGGCGTTTG*topo* (3′ end, reverse)giiR8TGTTCTACCCGACACATTTCTGIntron (5′ end, reverse)ip3FAGACCCACTATTTACAGATG*topo* (5′ end, forward)Ent1TACTGACAAACCATTCATGATG[@DKQ219C60]Ent2AACTTCGTCACCAACGCGAAC[@DKQ219C60]

Group II intron characterization
--------------------------------

Intron RNA secondary structure predictions were performed by the mfold server v. 3.2^[@DKQ219C36],[@DKQ219C37]^ and classification was based on group II intron consensus structures.^[@DKQ219C38]^ The broader distribution of the group II intron, and its presence in the topoisomerase I gene, was investigated among the 28 *vanA* plasmids isolated from the *E. faecium* strain collection (Table [1](#DKQ219TB1){ref-type="table"}) by PCR with the primers giiF/giiR3 and ip3F/giiR7 (Table [3](#DKQ219TB3){ref-type="table"}) and JumpStart *Taq* DNA Polymerase, as described above. RNA extraction and subsequent RT--PCR were used to confirm intron splicing. From overnight cultures of *E. faecium* 399/S99/A7 and *E. faecium* 399/F98/A4, 10 µL of each culture was transferred to 10 mL fresh BHI broth and further cultured to a density of ∼1 × 10^8^ cells. The cell cultures were treated with RNA*later* (Ambion), according to the supplier\'s protocol, followed by total RNA extraction by QIAGEN RNeasy Mini kit and DNaseI treatment with QIAGEN RNase-Free DNase (QIAGEN). RNA extracts were verified free of DNA contamination by using 1 µg of total RNA as template in a PCR with the DyNAzyme II DNA polymerase (Finnzymes). cDNA syntheses were done using the SuperScript III enzyme (Invitrogen) on ∼1 µg of total RNA as template and, in other respects, according to protocol. RT--PCRs were carried out with the primers given in Table [3](#DKQ219TB3){ref-type="table"}. The RT--PCR cycling parameters used were denaturation at 94°C for 2 min followed by 30 PCR cycles of 94°C for 45 s, 58°C for 30 s and 72°C for 30 s to 1.5 min (depending on the length of the product), and a final extension at 72°C for 5 min. The products were analysed by agarose gel electrophoresis and stained with ethidium bromide. To confirm the splicing boundaries, the PCR fragments of ligated exons were sequenced.

Results
=======

General features of the VanA-type plasmids pIP816 and pVEF4
-----------------------------------------------------------

The complete sequence of the plasmid pIP816 was determined and a partial sequence of pVEF4 is presented. pIP816 was extracted from the first glycopeptide-resistant *E. faecium* reported (strain BM4147) and was sampled from a patient with leukaemia in France in 1986.^[@DKQ219C13]^ pVEF4 was isolated from an *E. faecium* strain (399/F98/A4) sampled from poultry in 1998 on a Norwegian poultry farm where avoparcin was previously used as a growth promoter.^[@DKQ219C21]^ pIP816 (EMBL accession no. AM932524) is 34 616 bp in size, and has 36 CDSs and an average G + C content of 36.9% (Figure [1](#DKQ219F1){ref-type="fig"} and Table [4](#DKQ219TB4){ref-type="table"}). The partial sequence of pVEF4 (EMBL accession no. FN424376) is 44 443 bp in length, and has a G + C content of 36.2% and 46 CDSs (Figure [1](#DKQ219F1){ref-type="fig"} and Table [5](#DKQ219TB5){ref-type="table"}). Repeated attempts were made to achieve gap closure, but we did not succeed. We do, however, include the 44.4 kb partial, single sequence in this study, because it provides valuable additional information for the analysis of Tn*1546* junctions (see below) as well as on the composition of the overall *E. faecium* plasmid pool. Similarity searches identified 31 and 39 CDSs with known or predicted functions in pIP816 and in pVEF4, respectively. pIP816 and pVEF4 both encode a pseudo-streptomycin resistance gene (*str*) that the Tn*1546* transposon has transposed into, as well as genes involved in plasmid partitioning, a resolvase, truncated transposases and a hypothetical protein (Figure [1](#DKQ219F1){ref-type="fig"}). A topoisomerase is also present on both plasmids, but in pVEF4 a group II intron with an intron-encoding protein (CDS19) was identified inserted into the *topo* gene (see below). The entire Tn*1546* transposon, with the 38 bp inverted repeats together with the 5 bp direct repeats (5′-GTCCT-3′) of the Tn*1546* target site in *str*, is conserved in both plasmids. Table 4Coding sequences (CDSs) of the circular *vanA* plasmid pIP816CDS^a^Protein length (amino acids)Database matchAmino acid identity (%)1*tnp* Tn*1546*988pIP816 Tn*1546* transposase (Q06238)1002*res* Tn*1546*191pIP816 resolvase (Q06237)1003*vanR*231pIP816 VanR protein (Q06239)1004*vanS*384pIP816 VanS protein (Q06240)1005*vanH*322pIP816 VanH protein (Q05709)1006*vanA*343pIP816 VanA protein (P25051)1007*vanX*202pIP816 VanX protein (Q06241)1008*vanY*303pIP816 VanY protein (P37711)1009*vanZ*161pIP816 VanZ protein (Q06242)10010*str*′188N-terminal part of pS194 streptomycin resistance protein, *Staphylococcus aureus* (P12055)9511*tnp*′176pLI100 transposase, *Listeria innocua* (CAC42047)9812ω71pSM19035 transcriptional repressor ω, *Streptococcus pyogenes* (YP_232757)10013δ298pIlo8 δ protein, *Oenococcus oeni* (CAD70616) / pSM19035 active partitioning δ protein, *S*. *pyogenes* (YP_232765)100/9814*topo*714pAMβ1 type 1 topoisomerase, *Enterococcus faecalis* (AAC38606)9715*resIP*205pGB354 resolvase, *Streptococcus agalactiae* (AAB48454)10016*hcp*56pRE25 *orf7* hypothetical conserved protein, *E. faecalis* (CAC29163)10017*repE*497pAMβ1 RepE replication protein, *E. faecalis* (Q52249)10018*hcp*99pAMβ1 *orfD*, *E. faecalis* (Q52248)10019*copF*83pAMβ1 copy number repressor, CopF, *E. faecalis* (Q52247)10020*hcp*274pAMβ1 *orfC*, *E. faecalis* (Q52246)10021IS*1216*228IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786 and pE418 (e.g. CAC29206)10022IS*1252*319pHKK701 IS*1252* transposase (AAB42161)9923*res*190pRE25 *orf53* resolvase, *E. faecalis* (Q9AKZ9)10024*fic*201pRE25 *orf52* cell filament protein, Fic, *E. faecalis* (Q9AL00)10025*Integrase*′215Integrase, *Enterococcus faecium* DO (Q3Y1H6)8126*hcp*′214Plasmid2 hypothetical protein, *Nitrosomonas eutropha* C71 (Q3N6Z6)3927IS*1216*228IS*1216*, *E. faecium* (Q9KI43) / IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786, pUW1965 and pE418 (e.g. CAC29206)100/9928*prgO*91pRE25 PrgO protein, *E. faecalis* (Q9AKZ5)10029*prgP*317pRE25 PrgP protein, *E. faecalis* (Q9AKZ4)10030*repE*498pRE25 ORF1, putative replication protein, *E. faecalis* (Q9AL28)10031*prgN*98pRE25 PrgN protein, *E. faecalis* (Q9AL27)10032*hcp*283Hypothetical protein of *E. faecium* DO (EAN10371) / pRE25 hypothetical protein ORF4, *E. faecalis* (Q9AL25)100/9933IS*1216*228IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786 and pE418 (e.g. CAC29206)10034*tnp*′118pLI100 pLI0071 protein, putative transposase of *L. innocua* (Q925W6)8535*tnp*′114pLI100 pLI0020 protein, putative transposase of *L. innocua* (Q926N5)8736*str*′94C-terminal part of pS194 streptomycin resistance protein, *S. aureus* (P12055)95[^6] Table 5Coding sequences (CDSs) of the *vanA* plasmid pVEF4 (partial)CDS^a^Protein length (amino acids)Database match (accession number)Amino acid identity (%)1*hp*135---2*tnp*′118pVEF2 truncated transposase, C-terminal part (CAL90948)1003*tnp*′114pVEF1/pVEF2 truncated transposase, N-terminal part (CAL36541/CAL90947)1004*str*′94pS194 streptomycin resistance protein, *Staphylococcus aureus* (P12055)955*tnp* Tn*1546*988pIP816 Tn*1546* transposase (Q06238)1006*res* Tn*1546*191pIP816 resolvase (Q06237)1007*vanR*231pIP816 VanR protein (Q06239)1008*vans*384pIP816 VanS protein (Q06240)1009*vanH*322pIP816 VanH protein (Q05709)10010*vanA*343pIP816 VanA protein (P25051)10011*vanX*202pIP816 VanX protein (Q06241)10012*vanY*303pIP816 VanY protein (P37711)10013*vanZ*161pIP816 VanZ protein (Q06242)10014*str*′188pS194 streptomycin resistance protein, *S. aureus* (P12055)9515*tnp*′176pVEF1/pVEF2 truncated transposase, C-terminal part (CAL36529/CAL90935)10016ω71pVEF1/pVEF2 putative transcriptional repressor ω (CAL36528/CAL90934)10017δ298pVEF1/pVEF2 putative δ protein (CAL36527/CAL90933)10018*topo*715pVEF1/pVEF2 putative topoisomerase I (CAL36526/CAL90932)10019*iep*628pBc10987 group II reverse transcriptase, *Bacillus cereus* ATCC 109875920*res*205pVEF1/pVEF2 putative resolvase (CAL36525/CAL90931)10021*hcp*56pRE25 and pVEF1/pVEF2 hypothetical conserved protein (Q9AL24, CAL36524/CAL90930)10022IS*1216*′82IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786 and pE418 (e.g. CAC29206)9723*prgN*95pVEF1/pVEF2 putative PrgN protein (CAL36522/CAL90928)10024*repE*499pVEF1/pVEF2 putative replication protein (CAL36521/CAL90927)10025*ATPase*303pVEF1/pVEF2 putative ATPase (CAL36563/CAL90969)10026*hcp*123pVEF1/pVEF2 hypothetical protein (CAL36562/CAL09068)10027IS*1216*228IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786 and pE418 (e.g. CAC29206)10028*hcp*121pIP501 *orf7*, *Streptococcus agalactiae* (Q7AYQ0)10029ζ*′*84pVEF1/pVEF2 ζ toxin (CAL36553/CAL90959)9530*hcp*196pVEF1/pVEF2 hypothetical protein (CAL36558/CAL909064)9931*permease*537Putative tetronasin resistance transmembrane protein, *Streptococcus pyogenes* MGAS10750 (YP_603196)6932*ATPase*293Putative tetronasin resistance ATP-binding protein, *S. pyogenes* MGAS10750 (YP_603195)8533*regR*198pVEF1/pVEF2 putative regulatory protein, TetR family (CAL36555/CAL90961)9734*ltrC*374pMRC01 low temperature requirement C protein LtrC, *Lactococcus lactis* (AAC56005)5835IS*1216*228IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786 and pE418 (e.g. CAC29206)10036*int*278Putative integrase, catalytic region, *Enterococcus faecium* DO (EAN09812)9937IS*3*/IS*911*96Putative IS*3*/IS*911*, *E. faecium* DO (EAN09811)10038*repA*′137pEF418 putative replication protein, *Enterococcus faecalis* (AAL05545)9839IS*1216*′179IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786 and pE418 (e.g. CAC29206)10040*rep*′172pEFR putative replication protein, *E. faecium* (Q8KSS2)6641*repB*174pB82 replication protein RepB, *E. faecium* (A0JBS1)4942*hcp*93Hypothetical conserved protein, *E. faecium* DO (EAN10162)6043*hcp*138pEF1 *orf33* hypothetical conserved protein, *E. faecium* 6T1a (A3QN12)5544*abiF*258pNP40 abortive infection bacteriophage resistance protein, *L. lactis* DRC3 (AAB52386)5345IS*1216*228IS*1216* on pRE25, pRUM, pTEF1, pTEF3, pUW786 and pE418 (e.g. CAC29206)10046*hp*293Hypothetical protein---[^7] Figure 1Genetic map of pIP816 and pVEF4. Coding regions are represented by arrows indicating the direction of transcription and are coloured according to their predicted functions. The inverted repeats (IR) of the Tn*1546* transposon and the predicted origin of replication (*oriR*) of the plasmids are given as black boxes. The group II intron *En*.*fm*.I2 of pVEF4 is shown as dark grey boxes flanking the intron-encoding protein. Thin arrows indicate the 25 kb larger genetic unit. Truncated CDSs are indicated with a prime symbol (e.g. *tnp*′).

The plasmids pIP816 and pVEF4 contain putative CDSs involved in their own replication and maintenance. The replication of pIP816 is probably ensured through the replication protein RepE (CDS17) described in the Inc18 plasmid pAMβ1 from *E. faecalis*.^[@DKQ219C39]^ The origin of replication (*oriR*), copy number repressor (CopF), and hypothetical proteins ORFC and ORFD of pAMβ1 are also 100% conserved in pIP816 (Table [4](#DKQ219TB4){ref-type="table"}). Thus, pIP816 is predicted to replicate by a DNA polymerase I-dependent θ mechanism, such as pAMβ1.^[@DKQ219C40],[@DKQ219C41]^ pVEF4 encodes a replication protein (CDS24) previously reported in pVEF1 and pVEF2,^[@DKQ219C11]^ and an *oriR* identical to *oriR* of pAMβ1 is found downstream of the Rep protein. Recently, Jensen *et al*.^[@DKQ219C42]^ presented a classification system for plasmids from enterococci and other Gram-positive bacteria based on the conserved areas of the replication initiation genes (*rep*). According to this classification system, pIP816 groups into *rep* families 1 and 2, whereas pVEF4 is a member of group 1 (but also harbours an additional *rep* gene with limited sequence similarity to group 11). The presence of more than one *rep* gene may indicate increased host range, and groups 1 and 2 contain strains from *Enterococcus*, *Staphylococcus* and *Streptococcus*.

Genes involved in site-specific recombination (resolvases) and active partition processes of plasmids are found on pIP816 and pVEF4, putatively contributing to stable inheritance. Thus, the segregational stability of pIP816 is putatively under the control of the active partitioning systems delta-omega (δ-ω), as described for plasmid pSM19035 from *Streptococcus pyogenes*,^[@DKQ219C43]^ and/or the *prgP-prgO* gene products as described for pCF10 from *E. faecalis*.^[@DKQ219C44]^ Complete and fragmented insertion sequences (ISs) and transposases constitute 21% (*n* = 8) and 18% (*n* = 11) of the DNA sequence of pIP816 and the partial pVEF4, respectively. Inverted repeats of the IS*6* (5′-ggttctgttgcaaagttttaaatctactatcaaa-3′) or IS*30* families (5′-cgccgattgtaaaattaagctagacaaata-3′) are found along with most of the IS elements.

Comparative analysis of *vanA* plasmids
---------------------------------------

A genetic element (∼18 kb) including the non-conjugative Tn*1546* was found conserved between the *vanA* plasmids pIP816, pVEF1, pVEF2, pVEF3 and partial pVEF4. An additional 7 kb element, flanked by two IS*1216*, was present immediately upstream in pIP816 (inverted), pVEF1, pVEF2 and pVEF3 (Figure [2](#DKQ219F2){ref-type="fig"}). Thus, a common conserved genetic fragment of ∼25 kb was present in three *vanA* plasmids with a separate evolutionary history over \>13 years. Figure 2Gene organization of Tn*1546* and flanking areas in *vanA* plasmids from genomically different *E. faecium* strains of human or animal origin. Identical coding regions are colour-coded to highlight similarities in the Tn*1546* flanking regions. Similar colour indicates identity. White, Tn*1546*; red, IS*1216*; dark grey, intron *En*.*fm*.I2 and *iep*. Note that the ∼7 kbp region flanked by IS*1216* (red arrows) in pVEF1--pVEF3 is inverted in pIP816, and that similar organization was found in plasmids from two GREF from two Norwegian poultry farms (strains 399/F99/A8 and 64/F98/A1). The top line indicates the size of the aligned Tn*1546* flanking regions, with positional marks in kbp.

The presence of the conserved 25 kb *vanA*-containing fragment was further examined among a collection of 28 heterogeneous *vanA* plasmids, as determined by restriction fragment length polymorphism analyses (data not shown), from genomically different *E. faecium* strains of diverse epidemiology and geographical origin (Table [1](#DKQ219TB1){ref-type="table"}). The complete 25 kb fragment was only present in the completely sequenced pVEF1, pVEF2 and pVEF3. These three plasmids are present in genomically diverse strains, as previously shown by PFGE.^[@DKQ219C21]^ In pVEF1 and pVEF2, the 25 kb fragment is flanked by IS*1216*. Parts of the elements flanking the *vanA* gene cluster were also found on 15 additional plasmids. Of these, 12 were extracted from *E. faecium* strains sampled from Norwegian poultry farms (four poultry strains and eight poultry farmer strains at six different timepoints from 1998--2002) and three extracted from clinical strains (two from Norway and one from Portugal). Available multilocus sequence typing (MLST) data revealed that the different strains with intact or parts of the common Tn*1546*-containing fragment group into clonal complexes 1, 9, 17 and 22 (Table [1](#DKQ219TB1){ref-type="table"}).

DNA sequence alignment of the amplified plasmid fragments demonstrates high sequence identity, but a deletion of the δ gene was found for eight plasmids (Figure [2](#DKQ219F2){ref-type="fig"}). The 5′ end of Tn*1546* is inverted in pIP816 compared with pVEF1, pVEF2 and pVEF3, and both gene order patterns are found on other plasmids (Figure [2](#DKQ219F2){ref-type="fig"}).

pVEF4 encodes the group II intron *En*.*fm*.I2
----------------------------------------------

The annotation of the partial pVEF4 from *E. faecium* 399/F98/A4 identified a 2770 bp group II intron inserted into the topoisomerase I (*topo*) gene and it was named *En*.*fm*.I2 according to the mobile group II intron database nomenclature.^[@DKQ219C45]^ The predicted secondary RNA structure (Figure [3](#DKQ219F3){ref-type="fig"}a) shows that *En*.*fm*.I2 displays structural features similar to introns belonging to the bacterial class B of group II introns. *En*.*fm*.I2 carries a putative intron-encoded protein (IEP) (CDS19, Table [5](#DKQ219TB5){ref-type="table"}) located in domain IV, with domains responsible for the maturase function, reverse transcriptase function and endonuclease function (Figure [3](#DKQ219F3){ref-type="fig"}b). Figure 3Structural features of *En*.*fm*.I2 and its intron-encoded protein (IEP). (a) Predicted secondary RNA structure of *En*.*fm*.I2. Intron nucleotides are written in capital letters and exon sequences are written in lowercase letters. Roman numerals denote the domains I--VI. The IEP is found in domain IV. Intron-binding sites (IBSs) 1 and 2 along with the exon-binding sites (EBSs) 1 and 2 are marked by arrows and boxes, respectively. IBS/EBS3 is a single nucleotide interaction and denoted by pointing arrows. The bulged A (branch site) is located in domain VI and shown in bold. (b) The putative IEP displays a reverse transcriptase (RT) domain (bold letters), a maturase (X) domain (italics) and an endonuclease (En) domain (grey). All introns analysed, except two, had identical amino acid composition to *En*.*fm*.I2 of pVEF4 (no. 54, top). The non-synonymous substitutions in *En*.*fm*.I2 from *E. faecium* strains 31/F01/H (no. 49) and TUH32-79 (no. 45) are shown in the alignment (identical amino acids are represented by a dot; a dash indicates gaps or substitutions).

To test if the *En*.*fm*.I2 is a functional ribozyme and splices *in vivo*, total RNA was extracted, and RT--PCR was run with exon--exon-specific primers on DNA of pVEF4 and on pVEF3 as a negative control. *En*.*fm*.I2 intron splicing was established (Figure [4](#DKQ219F4){ref-type="fig"}, lane 1) and the ligated exons were confirmed by sequencing (data not shown). Specific primers targeting the intron--exon junctions (both 5′ and 3′) were used in RT--PCR reactions and confirmed the presence of unspliced intron in pVEF4, but not in the negative control (pVEF3) (Figure [4](#DKQ219F4){ref-type="fig"}). Primers amplifying the 2′--5′ junction allowed the identification of the splicing pathway of *En*.*fm*.I2 (Figure [4](#DKQ219F4){ref-type="fig"}, lanes 7 and 8). DNA sequencing of the generated PCR product showed that the *En*.*fm*.I2 forms a lariat structure *in vivo* with the 5′ end docking into the bulged A in domain VI. Figure 4RT--PCR analyses of the topoisomerase, intron, intron splicing products and enterococcal elongation factor. RT--PCR products from pVEF4 and pVEF3 are given on alternate lanes 1--10. PCR products are shown as follows: *topo* mRNA without intron (lanes 1 and 2, primer pair ip3F/giiR7); 5′ intron--exon junction (lanes 3 and 4, primer pair ip3F/giiR8); 3′ intron--exon junction (lanes 5 and 6, primer pair giiF5/giiR7); intron lariat structure (lanes 7 and 8, primer pair giiF5/giiR8); and positive RT--PCR control (lanes 9 and 10, primer pair Ent1/Ent2). Ladder (lanes L), 100 bp DNA molecular size marker from New England Biolabs. The sequence data of the ligated exon with the indicated splice site is shown in the lower half of the figure.

Distribution of the intron *En*.*fm*.I2 in *vanA* plasmids
----------------------------------------------------------

Because the *topo* gene and *En*.*fm*.I2 of pVEF4 were found adjacent to Tn*1546*, the wider presence of *En*.*fm*.I2 was determined among the 28 heterogeneous *vanA* plasmids (Figure [2](#DKQ219F2){ref-type="fig"}). In total, 15 *En*.*fm*.I2-encoding plasmids were identified, for which 14 of the *En*.*fm*.I2 introns were found localized in the *topo* gene. The intron-positive PCR products were confirmed by sequencing (data not shown). A highly conserved DNA sequence identity over the entire intron, including the IEP, was found. Only two of the *En*.*fm*.I2 introns (from *E. faecium* strains 31/F01/H and TUH32-79) displayed non-synonymous substitutions in the IEP protein (Figure [3](#DKQ219F3){ref-type="fig"}b).

Discussion
==========

We present the complete sequence of pIP816, the first *vanA* plasmid isolated in France 1986, as well as a partial, annotated sequence of the fourth plasmid isolated from a single Norwegian poultry farm, pVEF4. The comparative analyses with other completely sequenced *vanA* plasmids reveal that pVEF1--pVEF4 share a common genetic element of ∼18 kb that spans the entire Tn*1546* transposon, a topoisomerase I (*topo*) gene and the genes encoding the active partitioning system δ-ω of plasmid pSM19035^[@DKQ219C43]^ upstream of the *vanA* gene cluster. Three shared CDSs are located downstream of Tn*1546*.

Surprisingly, an identical (\>99% identity at the nucleotide level) 18 kb fragment is present in pIP816. When the inverted fragment located upstream is included, the size of the common fragment present in pIP816, pVEF1, pVEF2 and pVEF3 is ∼25 kb. The observation that the same plasmid-borne DNA fragment (harbouring Tn*1546*) was found on a Norwegian poultry farm 13 years after the original isolation of pIP816 in a clinical isolate in France^[@DKQ219C13]^ suggests either successful clonal spread or horizontal transfer between *E. faecium* strains of different origins. As determined by Werner and colleagues,^[@DKQ219C46]^ the pIP816 host BM4147 belongs to the MLST clonal complex (CC) 22, one of three CCs considered to be host-specific for humans (CC17, CC22 and CC94).^[@DKQ219C47]--[@DKQ219C49]^ In contrast, most of the strains isolated from the Norwegian poultry farms (of both poultry and farmer origin) belong to CC9, considered to be host-specific for poultry (including the hosts of pVEF1 and pVEF2).^[@DKQ219C47],[@DKQ219C48]^ This observation is consistent with the suggested horizontal transfer of a mobile genetic unit larger than Tn*1546* between different clonal complexes of *E. faecium*, although the direction and frequency of transfer is uncertain.

Tn*1546* was found inserted into a streptomycin resistance gene and conserved direct repeats were found in all *vanA* plasmids studied. The majority of these host strains were from Norwegian poultry farms previously exposed to avoparcin. Available MLST typing data^[@DKQ219C22],[@DKQ219C46],[@DKQ219C47],[@DKQ219C50]^ showed that the different MLST types clustered into CC9. These data further extend previous reports of the successful spread of a common plasmid-mediated genetic element surrounding Tn*1546* on Norwegian poultry farms.^[@DKQ219C21],[@DKQ219C22]^ Our observation is also consistent with the original pIP816 characterization with respect to insertion junctions,^[@DKQ219C23]^ and a recent Tn*1546* junction fragment analysis of *E. faecium* strains from the UK, Denmark, the Netherlands and Norway;^[@DKQ219C51]^ presenting evidence of the geographical distribution of two different Tn*1546*--plasmid insertion junctions. Garcia-Migura *et al*.^[@DKQ219C51]^ hypothesize that a common genetic element has spread across different clonal lines within the European broiler sector. The data presented here shed light on the composition and size of this element. Moreover, our data also suggest genetic interactions between *E. faecium* in animal reservoirs and CC17, the only *E. faecium* clinical high-risk CC.^[@DKQ219C47],[@DKQ219C49]^ Strain TUH32-76, a clinical CC17 GREF isolate from Portugal, displays Tn*1546* insertion in the streptomycin resistance gene and two immediately adjacent CDSs are linked to the 5′ end of the *vanA* gene cluster.

Tn*1546* belongs to the non-conjugative class II transposable elements of the Tn*3* family^[@DKQ219C52]^ and transfers intracellularly by replicative transposition to diverse sites.^[@DKQ219C23]^ Thus, the expected transfer by replicative transposition is inconsistent with the genetic patterns observed flanking the Tn*1546* transposon reported here and elsewhere.^[@DKQ219C51]^ Our data, as well as previous experimental results,^[@DKQ219C23]^ do not support the hypothesis that the streptomycin resistance gene represents a hotspot for Tn*1546* integration.

A detailed look at the plasmid sequences analysed here reveals that IS*1216* is present in one or both flanking regions of the larger glycopeptide resistance-encoding region (of 18--25 kb), suggesting movement of Tn*1546* as part of a composite transposon. Composite transposons are well known to mobilize antibiotic resistance genes in enterococci, e.g. Tn*5281* flanked by IS*256*, Tn*1547* flanked by IS*16*- and IS*256*-like elements, and Tn*5385* flanked by IS*1216*.^[@DKQ219C8],[@DKQ219C9],[@DKQ219C53]^ Composite transposition enabled by the IS*1216* elements flanking the *vanA* operon has also previously been described.^[@DKQ219C54]^ The authors showed that IS*1216* elements facilitated the transfer of Tn*1546* from a non-conjugative plasmid to a pheromone-responsive conjugative plasmid present in the same enterococcal cell, with subsequent intercellular transfer of the *vanA* gene cluster.

The broader comparative analysis of the genetic composition and gene order (synteny) of pIP816 and the pVEF-type *vanA* plasmids reveals multiple copies of plasmid replication and maintenance genes interspersed with several copies of IS elements. The mosaic plasmid structures indicate frequent formations of plasmid hybrids, recombination and transposition events. Interestingly, no known conjugal transfer genes have been found in any of the completely sequenced *vanA* plasmids from Norwegian poultry farms. This, however, does not mean that the plasmids or parts of them are constrained to a single strain. Plasmid co-transfer by the conjugative transposon Tn*916* has been reported in enterococci.^[@DKQ219C55]^ Conjugative mobilization of enterococcal plasmids has also been reported.^[@DKQ219C5],[@DKQ219C10]^

The sequence comparison of the *E. faecium vanA* plasmids enabled the discovery of the novel group II intron *En*.*fm*.I2 inserted into the *topo* gene of pVEF4. Mobile genetic group II intron elements are commonly found in bacteria, although they are not well characterized in enterococci.^[@DKQ219C45]^ The intron *En*.*fm*.I2 belongs to the group II bacterial class B introns, has an IEP that displays features of a multifunctional protein that might enable its mobility and follows the standard group II intron splicing pathway.^[@DKQ219C28]^ Bacterial mobile group II introns are generally site-specific on insertion and rapidly spread horizontally.^[@DKQ219C56]^ However, *vanA* plasmids encoding intron-free *topo* genes were detected in *E. faecium* strains (64/F98/H2 and 64/F98/H1) of human origin (one farmer) sampled at one poultry farm on the same occasion, where both plasmids are *topo*-encoding but only one is invaded by *En*.*fm*.I2.

In conclusion, comparative analysis of the original *vanA* plasmid pIP816 with the recently sequenced pVEF-type plasmids revealed a conserved genetic fragment (including Tn*1546*) of 18--25 kb. Taken together, the data show that VanA-type glycopeptide resistance is present in different clonal complexes of *E. faecium* and suggests that glycopeptide resistance can be disseminated through IS*1216*-facilitated composite transposition.
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[^1]: MLST, multilocus sequence type; PFGE, pulsed-field gel electrophoresis; CC, clonal complex; ND, not determined.

[^2]: ^a^ci, clinical isolate; cs, community survey; ho, hospital outbreak; hs, hospital survey.

[^3]: ^b^CC, clonal complex, extracted from references.^[@DKQ219C22],[@DKQ219C45],[@DKQ219C48],[@DKQ219C49],[@DKQ219C56]^

[^4]: ^c^K-res, Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway.

[^5]: ^a^The *vanA* plasmid (pHTβ) isolated from an *E. faecium* strain in Japan was included in the presented analysis. However, no DNA sequence identity was found, except from the presence of Tn*1546*.

[^6]: ^a^Prime indicates truncated CDS; *hcp*, hypothetical conserved protein.

[^7]: ^a^Prime indicates truncated CDS; *hcp*, hypothetical conserved protein; hp, hypothetical protein.
